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Abstract
Background: Huntington’s disease (HD) is a severe inherited neurodegenerative disorder characterized, in addition to
neurological impairment, by weight loss suggesting endocrine disturbances. The aims of this study were to look for
neuroendocrine disturbances in patients with Huntington’s disease (HD) and to determine the relationship with weight loss
seen in HD
Methods and Finding: We compared plasma levels of hormones from the five pituitary axes in 219 patients with genetically
documented HD and in 71 sex- and age-matched controls. Relationships between hormone levels and disease severity,
including weight-loss severity, were evaluated. Growth hormone (GH) and standard deviation score of insulin-like growth
factor 1 (SDS IGF-1) were significantly higher in patients than in controls (0.25 (0.01–5.89) vs. 0.15 (0.005–4.89) ng/ml,
p=0.013 and 0.1661.02 vs. 0.0660.91, p=0.039; respectively). Cortisol was higher (p =0.002) in patients
(399.146160.5 nmol/L vs. 279.86130.1 nmol/L), whereas no differences were found for other hormone axes. In patients,
elevations in GH and IGF-1 and decreases in thyroid-stimulating hormone, free triiodothyronine and testosterone (in men)
were associated with severity of impairments (Independence scale, Functional score, Total Functional Capacity, Total Motor
score, Behavioral score). Only GH was independently associated with body mass index (b=20.26, p=0.001).
Conclusion: Our data suggest that the thyrotropic and in men gonadotropic axes are altered in HD according to the severity
of the disease. The somatotropic axis is overactive even in patients with early disease, and could be related to the weight
loss seen in HD patients.
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Introduction
Huntington’s disease (HD) is a rare, autosomal dominant,
neurodegenerative disorder resulting from expansion of a CAG
repeat within the IT15 huntingtin (htt) gene on chromosome 4p
[1]. Mutant huntingtin protein produced in the cytoplasm forms
nuclear aggregates, which induce neuronal degeneration, most
notably in the cerebral cortex and striatum [2]. Progressive
neuronal death occurs in the tuberal nucleus of the lateral
hypothalamus in patients [2–7] and transgenic mouse models [7].
This lateral hypothalamic abnormality would be expected to affect
the function of most of the pituitary axes (as shown in other
neurodegenerative diseases where neuroendocrine alterations
occur [8]), potentially modifying the basal levels of GH, TSH,
ACTH, LH, FSH, and prolactin, at least at late in the course of
HD. However, the few available data on neuroendocrine function
in HD are conflicting.
Basal GH levels were higher in HD patients than in controls in
one study [9] and similar in another [10]. GH release in response
to bromocriptine increased [11] or remained unchanged [10].
Excessive GH release was noted in response to arginine infusion or
falling glucose levels [12,13]. Prolactin levels were decreased
[14,15], increased [11], or unchanged [10,16]. Cortisol levels were
high [17,18]. Thyroid stimulating hormone (TSH) was similar in
patients and controls [19], and testosterone was decreased in male
patients [20]. The discrepancies between axes and studies may be
related not only to methodological factors, but also to differences
across axes regarding the mechanisms that influence hormone
production. Each study focused on a single pituitary axis, which
precluded comparisons of axes within the same cohort. In
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studies had no control group, and the neuroendocrine effects of
neuroleptic treatment were not always taken into account. Thus,
available studies fail to provide a comprehensive picture of
neuroendocrine function in patients with HD.
In other neurodegenerative diseases, neuroendocrine alter-
ations are either independent from the phenotype, being directly
induced by the disease process, or related to the phenotype (as a
cause or a consequence) [8]. Neuroendocrine alterations in HD
may develop over time in relation to the phenotype, as a result of
advanced neuronal degeneration (e.g., causing atrophy of the
pituitary gland) and progression of the disease. Alternatively,
they may occur early on, in relation to the disease process, i.e., to
proximal effects of the mutant huntingtin protein. The effects of
the many protein-huntingtin interactions reported to date
remain to be evaluated but may include selective disturbances
in the hypothalamo-pituitary axes [21,22]. If such is the case, the
neuroendocrine disturbances would be expected to occur early
according to the presence of mutant huntingtin protein from
birth.
Weight loss is a characteristic feature of HD [23,24], in addition
to the neurological symptoms (chorea, cognitive impairment, and
behavioral disturbances) [3]. Weight loss was first thought to be a
consequence of increased energy consumption due to chorea.
However, it is now acknowledged that weight loss can develop
despite minimal involuntary movements [23,25]. A recent study
demonstrated a direct link between weight loss and CAG repeat
length [26]. As well, endocrine abnormalities that influence weight
[27] may cause the weight loss seen in HD.
We conducted a multicenter case-control study of the five
anterior pituitary axes (somatotropic, thyrotropic, corticotropic,
gonadotropic, and prolactin production) in a large cohort of
patients with HD and in age- and sex-matched controls. Our
primary objective was to look for neuroendocrine disturbances in
patients with Huntington’s disease (HD). Our secondary objective
was to evaluate relationships linking plasma hormone levels,
disease severity, and severity of weight loss.
Results
The clinical characteristics of the patients and their controls are
reported in Table 1. The patient cohort covered a broad age range
(27–85) and was evenly distributed between males (n=110) and
females (n=108). Disease severity was mild to moderate in most
patients (31% stage I, 38% stage II, 23% stage III, and 9% stage
IV–V), the number of CAG repeats was high (38 to 61), and mean
age at symptom onset was 43.6 years 610.5. Neuroleptics were
used by 121 (56%) patients (40% typical neuroleptics, 59%
atypical neuroleptics, and 1% both), antidepressants by 61% of
patients, and tranquillizers by 37% of patients.
Mean BMI and weight were significantly lower in the patients
(22.863.5 and 65.32612.75 kg, respectively) than in the control
group (24.764.2, p=0.004 and 71614 kg, respectively)
(p=0.012).
Somatotropic axis
Mean plasma GH level was significantly higher in HD patients
than in controls (0.25 ng/ml [0.01–5.89] vs. 0.15 ng/ml [0.005–
4.89], p=0.04). The difference remained significant after adjust-
ment for potential confounders including age, sex, BMI, and
neuroleptic treatment (p=0.017) (Table 2). Plasma GH was higher
in patients who did not taking neuroleptics (n=96, 0.38 ng/ml
[0.01–10.24]), compared to their matched controls (n=58,
0.14 ng/ml [0.004–4.57], p=0.001) and to HD patients who
was taking neuroleptics (n=121; 0.18 ng/ml [0.01–3.16],
p,0.001).
Plasma IGF-1 and IGF-1SDS values were significantly higher in
the HD patients than in the controls (154.45649.20 mg/L vs.
142.35641.66 mg/L, p=0.042 and 0.1661.02 vs. 0.0660.91,
p=0.039; respectively). GH was the only pituitary hormone whose
levels were significantly different between patients with early-stage
HD (stage 1 or 2) and controls (p=0.05), suggesting early
dysfunction of the somatotropic axis.
Corticotropic axis
ACTH concentrations were not significantly different between
the patients (n=219) and the controls (n=71) (Table 2). However,
plasma cortisol was higher in HD patients (399.146160.5 nmol/
L) than in controls (279.816130.05 nmol/L, p,0.001). This
difference persisted after adjustment for age, BMI, neuroleptics,
and ACTH (p=0.002). Plasma cortisol was higher in HD patients
who were not taking neuroleptics than in their matched controls
(409.496152.45 nmol/L vs. 289.456130.32 nmol/L, p=0.001).
Thyrotropic axis
As shown in Table 2, none of the thyrotropic axis hormones
differed significantly between the HD patients and the controls
group in the multivariate analysis.
Gonadotropic axis in men
Since information on menopausal and menstrual cycle phase at
the time of blood sampling for hormone assays was not available,
we neglected the results in women and focused on those of men.
LH, FSH, and testosterone concentrations showed no significant
differences between all male HD patients and all male controls
(Table 2).
Table 1. Baseline characteristics of the patients with
Huntington’s disease and their age- and sex-matched
controls.
Patients (n=217) Controls (n=71)
Age, years 52.23610.52 (27–85)
* 56.3613.0 (26–84)
Females, n (%) 107 (49) 35 (49)
Weight, kg 65.32612.75 (40–103)
* 71.0614.0 (47–105)
Height, m 1.6860.09 (1.47–1.92) 1.6960.10 (1.49–1.98)
Body mass index, kg/m
2 22.863.52 (15.04–39.56)
***
24.764.24 (17.67–34.81)
Age at onset, years 43.6610.5 (22–75) -
(CAG) repeat length 45.063.8 (38–61) -
UHDRS Functional assessment
Functional score 32.266.4 (24–50) -
Independence scale 78.0616.7 (10–100) -
TFC score 7.963.4 (0–13) -
UHDRS Behavioral score 17.4612.2 (0–61) -
UHDRS Motor score 41.3623.0 (1–110) -
Data are means6SD (range) or % (n).
TFC, Total Functional Capacity; UHDRS, Unified Huntington’s Disease Rating
Scale.
*p#0.05.
**p#0.01.
***p#0.005.
doi:10.1371/journal.pone.0004962.t001
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Prolactin levels were significantly higher in the patients than in
the control group (15.39 mg/L [2.08–114.8] vs. 8.65 mg/L [2.51–
29.51], p,0.001) (data not shown). Prolactin level elevation is a
well-known effect of neuroleptics. HD patients who were taking
neuroleptics (n=121) had significantly higher prolactin levels,
compared to the age-sexe matched controls (n=66; 21.98 [2.81–
186.2] mg/L vs. 8.27 [2.75–25.11] mg/L, p,0.001) and to the HD
patients who were not taking neuroleptics (n=96; 9.24 [2.51–
33.95] mg/L, p,0.001). There was no difference in prolactin levels
between HD patients who were not taking neuroleptics (n=96;
9.24 mg/L [2.51–33.97]) and their matched control group (n=58;
8.23 mg/L [2.95–22.90], not significant). After adjustment for
neuroleptic use, prolactin levels were not significantly different
between the patients and their matched controls (Table 2).
Because the difference between sexes on the levels of prolactin, we
evaluated prolactin levels separately for males and females.
Analyses of gender-matched populations yielded similar results
(data not shown).
Relationships between disease severity and plasma
hormone levels
GH (Table 2 and 3) was the only pituitary hormone that
increases significantly both in HD patients compared to controls
and across disease stages. IGF-1 increased with the severity of the
functional and motor impairments (Table 3). These relationships
remained significant in the multivariate analyses adjusting for age,
sex, neuroleptics, IGFBP3 for IGF-1, and BMI for GH.
Decreases in testosterone levels in men and in TSH and FT3 in
all patients occurred in parallel with disease severity as assessed by
Table 2. Comparison of plasma hormone levels in patients with Huntington’s disease patients and their age- and sex-matched
controls.
Plasma hormone levels Patients (n=217) Controls (n=71) p values
U
Somatotropic GH, ng/ml 0.25 (0.01–5.89) 0.15 (0.005–4.89) 0.017
IGF-1, mg/L 154.45649.20 142.35641.66 0.042
SDS IGF-1 0.1661.02 0.0660.91 0.039
IGFBP3, mg/ml 4.9560.98 4.9961.05 NS
Corticotropic ACTH, ng/L 7.9 (1.23–50.1) 7.06 (1.73–28.9) NS
Cortisol, nmol/L 399.146160.5 279.86130.0 0.002
Thyrotropic TSH, mIU/L 1.36 (0.25–7.6) 1.39 (0.23–8.12) NS
FT4, pmol/L 15.7463.3 16.4262.04 NS
FT3, pmol/L 4.7161.58 4.7560.52 NS
Gonadotropic (males only) (110 cases and 36 controls) LH, IU/L 3.92 (1.44–10.7) 4.81 (1.28–18.2) NS
FSH, IU/L 5.31 (1.65–16.9) 6.39 (1.69–24.0) NS
Testosterone, nmol/L 15.62 (4.67–39.81) 14.18 (4–30.69) NS
Prolactin Prolactin, mg/L 15.39 (2.08–114.8) 8.65 (2.51–29.51) NS
Data are arithmetic means6SD or geometric means (95% confidence interval). Adjustment was done on age, sex, BMI, neuroleptic treatment, and IGFBP-3 when these
parameters were significant in the univariate analysis. GH, growth hormone; IGF-1, insulin-like growth factor-1; SDS-IGF-1, standard deviation score of IGF-1; IGFBP3,
insulin-like factor binding protein-3; ACTH, adrenocorticotropic hormone; TSH, thyroid stimulating hormone; FT4, free total thyroxine; FT3, free triiodothyronine; LH,
luteinizing hormone; FSH, follicle-stimulating hormone; NS, not significant.
UP value of the multivariate model.
doi:10.1371/journal.pone.0004962.t002
Table 3. Relationship between disease severity and pituitary axis function.
Clinical features GH IGF-I ACTH Cortisol TSH FT3 FT4 FSH
{ LH
{ TT
{ Prolactin
I
Independence Scale 20.22
*** 20.14
** 20.007 20.09 0.17
** 0.19
** 20.05 20.02 20.10 0.25
** 20.05
Functional score 0.17
** 0.15
*** 20.04 0.02 20.19
** 20.22
*** 0.06 0.03 0.07 20.29
*** 0.06
TFC score 20.21
*** 20.13
** 20.02 20.01 0.21
*** 0.19
** 20.02 0.02 20.03 0.25
** 20.02
Total Motor score 0.15
** 0.10
* 0.07 0.06 20.09 20.23
*** 20.07 20.05 0.01 20.18
* 0.02
Behavioral score 0.03 20.001 20.04 20.09 20.12
* 20.01 0.009 0.01 0.04 20.20
** 20.02
Data are b coefficients of the linear regression. The multivariate linear regression model adjusted for age, sex, neuroleptic treatment, IGFBP3 when IGF-1 was in the
model, and BMI when GH was in the model.
*p#0.10.
**p#0.05.
***p#0.01.
GH, growth hormone; IGF-1, insulin-like growth factor-I; ACTH, adrenocorticotropic hormone; TSH, thyroid stimulating hormone; FT3, free triiodothyronine; FT4, free
total thyroxine; LH, luteinizing hormone; FSH, follicle-stimulating hormone; TT, testosterone; TFC, total functional capacity.
{Only males were included (110 patients).
IOnly patients not taking neuroleptics were included (96 patients).
doi:10.1371/journal.pone.0004962.t003
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behavioral score (Table 3).
Consistent with these results, in a multivariate analyze, the
cognitive impairment, measured in 98 patients, was also related to
the decrease in Testosterone in men and in FT3 and to the
increase in IGF-1. (Data not shown)
Relationship between body mass index and hormone
plasma levels
BMI showed significant negative relationships (Table 4) with
GH, cortisol, CAG repeat number, and motor UHDRS. These
relationships remained significant after adjustment for age and sex.
No other hormone was related to BMI (Table 4), including
testosterone in men (data not shown). In the multivariate analysis,
only GH was significantly related to BMI (b=20.26, R
2=0.12,
p=0.001) independently from age, gender, motor UHDRS, CAG
repeat number, and cortisol (Table 4).
Because a causal relationship between chorea and weight loss
has been suggested in HD patients, we assessed the relationship
between BMI and chorea. BMI was related to the chorea score in
the univariate analysis (b=20.15, p=0.03). In the multivariate
analysis, however, only GH was significantly associated with BMI,
independently from the chorea score (b=20.21, p=0.003).
Discussion
Endocrine disturbances in HD and their link with disease
severity have not been investigated previously in a large matched
case-control study, despite their pathophysiological and clinical
relevance [28]. We demonstrated impairments of several anterior
pituitary axes in HD patients (Figure 1). Both central (GH) and
peripheral (IGF-1) somatotropic hormones were higher in the
patients than in the healthy controls and increased with disease
severity. Among corticotropic-axis hormones, only cortisol was
increased. In contrast, the thyrotropic-axis and, in men,
gonadotropic-axis hormones were decreased with disease severity.
The prolactin was increased in patients with neuroleptic
treatment. Of the five axes, only the somatotropic axis was related
to weight loss.
Both typical and atypical neuroleptics treatment influence
hormonal levels of prolactin and GH by altering their dopami-
nergic regulation [29]. To avoid the biais of neuroleptic treatment,
firstly we adjusted on neuroleptics treatment in our multivariate
regression models. After, we compared hormonal levels in controls
and patients with and without neuroleptics treatment. Using this
approach, we found that the prolactin increase in the HD group
compared to the matched control group was entirely ascribable to
neuroleptic use. On the contrary, neuroleptics blunted partially
the high significant difference in GH levels between patients and
controls in the overall population. Indeed, this significant
difference in GH was higher in non-users group then in group
taking neuroleptics.
Basal plasma cortisol was higher in HD patients than in
controls, in keeping with earlier studies [17,18]. This increase was
independent from ACTH levels and from disease severity. The
dissociation of cortisol levels from ACTH levels suggests a role for
other factors in the cortisol increase seen in the patients. An earlier
study showed a blunted ACTH response to exogenous corticotro-
pin-releasing hormone [18]. Presumably, chronic stress may be
associated with alteration in the hypothalamo-pituitary axes and
particularly contributes to increase the cortisol levels [30] in the
patients, as seen in other chronic diseases such as schizophrenia
[31] and depression [32].
Alterations in sexual behavior have been reported in patients
with HD [33]. Our hormone level data fail to provide convincing
explanations to these alterations, as plasma testosterone levels were
not significantly different between HD patients and controls. An
earlier study showed lower testosterone levels in males with HD
compared to healthy controls [20]. However, the patients with
stage I or II disease had normal testosterone levels, and
testosterone levels showed a negative correlation with disease
severity [20]. Patients with stage I and II disease contributed 69%
of our study population and patients with stage IV or V only 9%.
In keeping with the earlier study [20], we found that testosterone
levels declined with disease severity. A transgenic mouse model of
HD (the R6/2 model) is characterized by atrophy of the testes and
infertility [34], which may be related to loss of hypothalamic
neurons producing gonadotropin-releasing hormone (GnRH)
[35]. The reduction in plasma testosterone levels in our patients
was not associated with decreases in FSH and LH, indicating a
role for loss of the direct neuronal hypothalamic-testicular
pathway in patients with advanced disease.
TSH levels in our patients did not differ significantly from those
in the controls but declined with disease progression, in keeping
with a previous study [19]. Since, none of the thyroid hormones in
our study differed between patients and controls, the declining
TSH levels suggest loss of hypothalamic neurons. However,
additional studies are needed to clarify this point.
Plasma GH levels were higher in patients than controls, in
accordance with previous reports [9,12]. A few studies conducted
in smaller numbers of patients found no increase in GH [10,16,36]
or IGF-1[37]. However, we found increases not only in GH, but
also in the GH effector (free IGF-1). Furthermore, this increased
somatotropic activity was associated with disease severity.
Importantly, weight loss was significantly related to GH elevation
and was independent from motor disorders and other endocrine
Table 4. Relationship between body mass index and clinical
and hormonal disturbances.
Clinical and hormonal BMI BMI
features Adjusted Analyses
1 Multivariate Analysis
2
GH 20.27
*** 20.21
***
IGF-1 20.14 -
ACTH 0.09 -
Cortisol 20.16
** 20.13
TSH 20.03 -
FT3 0.11 -
FT4 20.04 -
Age at symptom onset 0.10 20.01
CAG repeat number 20.21
* 20.16
UHDRS motor score 20.20
*** 20.16
CAG repeat number 20.21
* 20.16
UHDRS motor score 20.20
*** 20.16
Data are b coefficients (p value) of the linear regression.
1adjusted for age and sex.
2multivariate analysis including age, sex, and parameters significant in the
univariate analysis.
*p#0.10.
**p#0.05.
***p#0.01.
BMI, body mass index; GH, growth hormone; IGF-1, insulin-like growth factor-I;
ACTH, adrenocorticotropic hormone; TSH, thyroid stimulating hormone; FT4,
free total thyroxine; FT3, free triiodothyronine.
doi:10.1371/journal.pone.0004962.t004
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treatment decreases the fat mass by inducing lipolysis within fat
tissue [38]. Thus, increased GH release may be related to the
weight loss often seen in HD patients [24].
Concerning IGF-1, the present finding extend and reinforce the
observations that level of circulating IGF-1 is altered in many type
of human neurodegenerative disease. In HD, it may exert a
neuroprotective role by activating the enzyme serine/threonine
kinase Akt [21], which phosphorylates the mutant huntingtin
protein at serine 421. A protective effect of IGF-1 has been
suggested in other neurodegenerative diseases [39]. As well, this
elevation of IGF-1 level reflect a resistant state [40] and it is likely
due to a loss of sensitivity of target cell to the action of growth
hormone.
Therefore, prospective study is necessary to determine whether
GH increase is the cause or the result of weight loss and other
impairment and to verify if the IGF-1 elevation seen in our
patients could reflect an adaptive response to cell death.
In conclusion, our data advocate several neuroendocrine
abnormalities in HD. These alterations, although possibly non-
specific, may shed light on some of the pathophysiological
mechanisms involved in disease progression. Although neuroen-
docrine dysfunction may contribute to peripheral symptoms such
as weight loss, its link to disease progression remains to be
confirmed.
Materials and Methods
Participants
We enrolled 219 patients with HD characterized genetically by
a CAG repeat number greater than 38. These patients were
recruited at six centers (Cre ´teil, Paris, Marseille, Strasbourg, Lille,
and Lyon) belonging to an HD network (Re ´seau Huntington de
Langue Franc ¸aise, RHLF). The 108 females and 111 males with
HD had an average age of 52610?8 years (range 25–85). They
were compared to 71 healthy controls (35 females and 36 males)
recruited among spouses or close relatives of the patients and
matched to the patients on age and sex, two factors that affect
hormone production. The control group of spouses and close
relatives is needed to have the most identical group in all relevant
Figure 1. Levels of pituitary and peripheral hormones according to HD stage and comparatively to controls. An orange arrow: early
increase in hormone concentration compared to controls. A green arrow: increase in hormone concentration related to an exogenous factor
(neuroleptic treatment or stress). A blue arrow: late decrease in hormone concentration related to disease severity. GH, growth hormone; IGF-1,
insulin-like growth factor-I; TSH, thyroid stimulating hormone; FT3, free triiodothyronine; ACTH, adrenocorticotropic hormone; LH, luteinizing
hormone; FSH, follicle-stimulating hormone; TT, testosterone.
doi:10.1371/journal.pone.0004962.g001
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patients except for the disease in order to eliminate any factors that
alter the hormonal states. The control group had an average age of
56?3613 years (range 26–84).
We matched our patients and controls in a ratio of 3/1
respectively on both age and sex. For age, the interval of matching
was 1 to 3 years except for 3 patients and 2 controls who had an
interval of 7 to 10. This difference in matching strategy is not
anticipated to affect our results, given that it involves a limited
number of samples and the differences in hormone levels over a 10
year period is still anticipated to be negligible.
The controls were not at risk for HD and were free from
neurological disease. The study protocol was approved by the Henri
MondorEthicsCommittee(Cre ´teil,France).Beforeinclusion,written
informed consent was obtained from all patients and controls.
HD patients were assessed by the neurologist of the relevant
center. The assessment included a clinical examination using the
Unified Huntington’s Disease Rating Scale (UHDRS) [1], a medical
history, and a questionnaire on past and current symptoms.
The UHDRS is divided into four components that assess motor
performance, cognition, behavior, and functional capacity [41].
The motor score evaluates various features including chorea,
dystonia, and oculomotor function. The behavioral score measures
the frequency and severity of psychiatric symptoms.The functional
assessment comprises three sub-scales: the functional checklist
(range from 25 to 50), the Independence Scale (IS, range 0 to 100),
and the Total Functional Capacity scale (TFC, range 0 to 13). The
TFC distinguishes five stages, from I (slightly impaired) to V
(severely impaired) [42]. The cognitive assessment was evaluated
in only 98 patients and it comprises three tests: Stroop Interference
test, Symbol Digit Modalities Test and the Verbal Fluency Test.
Body mass index (BMI) was calculated as weight in kilograms
divided by height in meters squared. Medications were recorded,
including neuroleptics, antidepressants, tranquillizers, and other
drugs without known effects on plasma hormone levels. Three
patients were treated for hypothyroidism and were excluded from
the analysis of thyroid axis function. We also excluded 2 more
patients from all analysis since they had an age of onset inferior to
20 years old.
Hormone assays
Hormones produced by the five pituitary axes were assayed at a
central laboratory: somatotropic-axis hormones (growth hormone
[GH], insulin-like growth factor-1 [IGF-1], and insulin-like factor
binding protein-3 [IGFBP3]), thyrotropic-axis hormones (thyroid
stimulating hormone [TSH], free triiodothyronine [FT3], and free
total thyroxine [FT4]), corticotropic-axis hormones (adrenocorti-
cotropic hormone [ACTH] and cortisol), gonadotropic-axis
hormones (luteinizing hormone [LH], follicle-stimulating hormone
[FSH], and testosterone in men), and prolactin.
Blood samples were drawn in the morning after an overnight
fast for all individuals and stored at 280uC until used. Assays were
performed according to the manufacturer’s instructions for the
relevant kit. All samples were tested in a single run using a single
reagent lot. GH was assayed using ACCESS2 (Beckman-Coulter,
Villepinte, France); TSH, FT3, FT4, FSH, LH, prolactin,
testosterone, cortisol, and ACTH using ELECSYS2010 (Roche
Diagnostics, Meylan, France); and IGF-1 and IGFBP3 using
IMMULITE2500 (DPC, La Garenne Colombes, France).
Statistical analysis
Arithmetic means with their standard deviation (SD) were
computed for normally distributed variables. Variables whose
distribution was not normal (GH, TSH, ACTH, prolactin, LH,
FSH, and testosterone) were normalized by logarithmic or square-
root transformation, and their geometric means with the 95%
confidence intervals (95%CI) were computed. Since the normal
range of IGF-1 change according to age, all statistical analyses
were performed on SDS IGF-1 for IGF-1 concentration. We
calculated standard deviation score (SDS) of IGF-1 for each
individual according to the following formula [43]:
IGF-1 SDS~ IGF-1 concentration ðÞ { expected IGF-1 concentration in an age-matched population ðÞ ½  
SD of IGF1 concentration ðÞ
In addition, because IGFBP3 is the main binding protein for IGF-
1 and regulates its activity, the IGF-1 level was adjusted for
IGFBP3.
With our sample size and the 3:1 ratio of patients over controls,
power was greater than 90% for detecting a statistically significant
difference of about 20% between mean hormone levels in patients
and controls.
We used t-tests or chi-squared tests to compare patients and
controls. The multivariate analysis adjusted for age, sex, and
variables yielding significant results in the univariate analyses
(BMI, neuroleptic use, and IGFBP3). Since neuroleptics may
influence the levels of some hormones, we first adjusted for
neuroleptic use in overall analyses and we then compared HD
users of neuroleptics to HD non-users and to their controls. Since
hormone levels were not influenced by the use of antidepressants
or tranquillizers, these variables were not entered into the model
(data not shown).
Linear regression analysis was performed to evaluate associa-
tions between hormone levels and clinical characteristics. Adjust-
ments were done for age, sex, BMI, neuroleptic use, and IGFBP3,
which were significantly related to hormone levels in the univariate
analyses.
Differences were considered statistically significant when
p,0.05. All analyses were conducted using the SPSS 13.0 for
Windows package (SPSS Inc, Chicago, IL).
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